Interaction between islets and implantable immunoisolation polyurethane membranes

描述（由申请人提供）：生物人工器官（隔离的细胞培养物，植入隔离膜内）的开发因许多动态和相互关联的变量而变得复杂。一个主要变量是包含在膜中的细胞培养物与膜之间的关系，这将对隔离室提供所需治疗效果的能力产生直接影响。该1期SBIR资助申请将导致开发用于在膜室内机械分离胰岛簇或B细胞的方法。这项资助的第一个具体目标是测试在体外细胞培养实验中，在隔离膜内机械分离从新生大鼠收获的胰岛的可行性。该基金的第二个目的是确定B细胞与层粘连蛋白包被的聚氨酯膜之间的粘附特性。该资助的第三个目的是比较已通过机械手段分离的胰岛簇的胰岛素产生（具体目的1）与已通过粘附于层粘连蛋白包被膜而单独稳定的β细胞的胰岛素产生（具体目的2）。该I期项目的结果将直接影响临床上有用的细胞室装置的具体设计标准。通过研究胰岛、B细胞、聚氨酯膜和使用层粘连蛋白的表面改性之间的相互作用所获得的信息将为用于治疗1型糖尿病的较大医疗器械的结构、尺寸和容量提供重要的见解。我们打算与其他公司合作，在第二阶段赠款申请的同时进行特定设备的开发。

DESCRIPTION (provided by applicant): The development of bio-artificial organs (sequestered cell cultures, implanted within an isolating membrane) is complicated by many dynamic and interrelated variables. 1 major variable is the relationship between the cell cultures contained in the membrane and the membrane, which will have a direct impact on the ability of the sequestered chamber to provide the desired therapeutic effects. This Phase 1 SBIR grant application will result in the development of methods to be used for mechanically segregating pancreatic islets clusters or B cells within a membrane chamber. The first specific aim of this grant is to test the feasibility of mechanically separating islets harvested from neonatal rats within an isolating membrane during in-vitro cell culture experiments. The second aim of this grant is to determine the adhesion properties between B cells in culture with a laminin coated polyurethane membrane. The third aim of this grant is to compare the insulin production from islet clusters that have been segregated by mechanical means (specific aim 1) to insulin production from beta cells that have been individually stabilized by adhesion to the laminin coated membrane (specific aim 2). The results from this Phase I project will directly impact the specific design criteria of a clinically useful cell chamber device. The information gained by studying the interactions between islets,B-cells, the polyurethane membrane and surface modification using laminin will provide essential insight into the structure, dimensions and capacity of a larger medical device used for the treatment of type-1 diabetes. It is our intention to pursue the specific device development in concert with a Phase II grant application in conjunction with other corporate collaborations.